Post-market surveillance that turns field data into evidence
For device manufacturers: we write the PMS plan, then run literature surveillance and complaint-trend review to a written protocol. PMS reports, PSURs and clinical evaluations then rest on current evidence.
A system that keeps learning after launch
Under the EU MDR, post-market surveillance is a planned, proactive system, not a complaint inbox. Articles 83 to 86 require a PMS system and a PMS plan. They also require a PMS report for class I devices or a periodic safety update report for higher classes. Each output must feed risk management, clinical evaluation and the technical documentation.
Literature is often an under-used data source. Published studies, case reports and registry analyses can reveal failure modes or performance issues before your own complaints do. We run literature surveillance on a fixed schedule with a written search protocol and documented screening and appraisal. Each cycle is reproducible and traceable to your PMS plan. The same searches can supply the literature part of a post-market clinical follow-up (PMCF) plan.
We also help interpret complaint trends and public adverse event databases such as FDA's MAUDE. Report counts in these databases are not incidence rates, because they lack denominators and reflect reporting behavior. Our scientists read them alongside sales volumes, use patterns and the device's materials and design. Vigilance reporting decisions remain with the manufacturer.
Post-market surveillance support we provide
PMS plan
A plan aligned with MDR Annex III that names data sources, collection methods, indicators, thresholds and assessment methods. It links each source to updates of risk management and clinical evaluation.
Literature surveillance
Scheduled searches of literature databases using a documented protocol, with screening and appraisal of relevant hits. Each cycle produces a log of what was found and what it means for your device.
PMCF literature component
Literature activities written into your clinical follow-up plan, with search strategy, appraisal criteria and reporting frequency. Literature complements device-specific data from surveys, registries or studies; it does not replace them.
Trend analysis
Review of complaints and incidents over time, with methods and thresholds defined in advance. We support your assessment under MDR Article 88 of whether a statistically significant increase in non-serious incidents or expected side-effects needs a trend report.
PMS report and PSUR drafting
Draft PMS reports for class I devices and PSURs for class IIa, IIb and III devices. Each summarizes data, conclusions and actions taken; PSURs add the benefit-risk conclusion. Your team reviews and approves the final document.
Public database review
Searches of public adverse event and recall databases for your device and similar devices. We report what was found, its limits and whether it changes your risk picture, without treating counts as incidence.
How a surveillance engagement runs
Map your obligations
We confirm device classes, markets and existing PMS documents. From that we set out what each regulation requires, when each output is due and which data sources your plan must cover.
Build the protocol
We write or update the PMS plan and the literature search protocol, including databases, search strings, inclusion criteria and appraisal method. Your team approves both before the first surveillance cycle starts.
Run, report and feed back
Each cycle produces a documented log and summary. We flag findings that could affect safety or performance promptly, with a view on whether risk management, clinical evaluation or labeling needs review.
How post-market questions typically arrive
Biomaterial implant manufacturer
An implant maker needing scheduled literature surveillance
- Situation
- A manufacturer of a marketed resorbable implant checks the literature only before each PSUR is due. Its notified body has asked how literature is identified between reporting periods. It also wants to see how findings reach the risk management file.
- How we advise
- We would write a literature surveillance protocol covering the device, its materials and similar devices, with fixed databases, search strings and screening criteria. Searches would run monthly. Relevant hits would be appraised for safety and performance signals, such as degradation-related inflammation or migration. Monthly logs would build a cumulative summary that supports the PSUR and the clinical evaluation update.
- What you receive
- A surveillance protocol, monthly screening logs, appraisal notes for relevant hits, a cumulative summary for the PSUR and prompt flags on potential signals.
Wound care device company
A PMCF plan without a literature component
- Situation
- A wound care device company's PMCF plan relies on a user survey alone. Its notified body asked for a broader approach. That includes a systematic literature review of the device and comparable devices, with clear links to the clinical evaluation.
- How we advise
- We would add a literature component to the plan, following the structure of the MDCG 2020-7 template. The section would set objectives, search method, appraisal criteria and how results feed the evaluation report. We would check that each objective links to a residual risk or clinical claim. The literature work then answers real questions rather than generating volume.
- What you receive
- A revised plan section, a literature search protocol and a reporting template that matches the structure of the PMCF evaluation report.
Orthopedic device manufacturer
A complaint trend that may also appear in the literature
- Situation
- A manufacturer sees an increase in complaints about early loosening of a device. Before deciding on trend reporting or field action, it wants to know whether published studies and public adverse event databases describe the same problem.
- How we advise
- We would search the literature for loosening and related failure modes in the device and comparable devices, and review public databases such as MAUDE. Database report counts cannot be read as incidence, because they lack denominators and reflect reporting behavior. We would compare the complaint rate with sales data and published rates where available, then summarize what the evidence supports.
- What you receive
- A short evidence memo covering literature findings, public database results and their limits, as input to the manufacturer's trend reporting and vigilance decisions.
Illustrative scenarios. Each is a composite of common client situations, not a specific engagement.
Start with a defined piece of work
Frequently asked questions
What does the EU MDR require for post-market surveillance?
Articles 83 to 86 require each manufacturer to run a PMS system proportionate to the device's risk class, documented in a PMS plan. Class I devices need a PMS report. Class IIa, IIb and III devices need a PSUR, updated at least every two years for class IIa and at least annually for classes IIb and III.
Is literature surveillance enough for PMCF?
Usually not on its own. MDR Annex XIV Part B describes it as proactive collection of clinical data on the device itself. Literature can cover similar devices and the state of the art, but notified bodies often expect device-specific data as well. We help define where literature fits and what else your plan needs.
What do you need from us to start monthly literature surveillance?
Your device description, intended purpose, materials, current clinical evaluation report, risk management summary and any existing search strategy. We also need the comparable devices you consider relevant. With these, we draft the protocol for your approval before the first monthly cycle runs. All work is done remotely.
Can you file vigilance reports for us?
Vigilance reporting decisions and submissions remain with the manufacturer. We help assess whether an event or trend may meet reporting criteria, prepare supporting evidence and draft documents for your review. Your regulatory or quality lead decides whether and when to report, and submits through the required channels.
Do you support US post-market requirements too?
Yes, for evidence work. We review MAUDE and recall data, support complaint trending and prepare inputs for medical device reporting decisions under 21 CFR Part 803. Postmarket surveillance studies ordered by FDA under Section 522 need study design beyond literature work, which we can discuss and scope separately.
Keep your post-market evidence current
Share your device class, markets, and current PMS plan. We’ll follow up by email and send a quote that sets out the proposed work.
Neucite Consulting supports post-market surveillance with evidence and draft documents; the manufacturer remains responsible for its PMS system, vigilance reporting and all regulatory submissions.